GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has approved extending the use of ...
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, ...
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...
Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as ...
This morning Belgian startup Indigo Diabetes announced a €38 million ($44.6 million) Series B funding round. This round included contributions from new investors Fund+, Ackermans&van Haaren, Capricorn ...
GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 15-day Dexcom G7 had a MARD of 8%, a small ...
Diabetes remains one of the nation’s most prevalent and dangerous chronic conditions, affecting nearly 15% of U.S. adults and causing more than 100,000 deaths each year. As a response, the landscape ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of ...